GL1X · GenesisL1 explorer

MolNFT v1 · #156718 · protein

Non-receptor protein tyrosine phosphatase SHP2 in complex with allosteric inhibitor pyrimidinone 7

6MD7 · Tyrosine-protein phosphatase non-receptor type 11: “Non-receptor protein tyrosine phosphatase SHP2 in complex with allosteric inhibitor pyrimidinone 7”. X-ray diffraction, 2 ligands (JE1, PO4), 15 pockets (best druggability 0.68).…

PDB
6MD7
Type
protein
Length
985 residues
Chains
2
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Tyrosine-protein phosphatase non-receptor type 11
EC
3.1.3.48
UniProt
Q06124
Ligands
JE1, PO4
Pockets
15 · best druggability 0.68

Structure

x-ray diffraction · 2 distinct chains · 31% helix, 25% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
ATyrosine-protein phosphatase non-receptor type 11 (EC 3.1.3.48)protein49631% helix, 25% strandQ06124
BTyrosine-protein phosphatase non-receptor type 11 (EC 3.1.3.48)protein48931% helix, 26% strandQ06124

Ligands and binding sites

  • JE1 · 2-[4-(aminomethyl)-4-methylpiperidin-1-yl]-5-{[2-(trifluoromethyl)pyridin-3-yl]sulfanyl}pyrimidin-4(3H)-one · ligand · 2 copies · chains A, B
  • PO4 · Phosphate ion · ion · 11 copies · chains A, B

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

15 pockets found on a 1 Å grid, 4 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
18060.680.7560empty
24130.670.8035JE1, PO4
34410.660.7939JE1, PO4
41530.550.8125PO4
51000.500.8220PO4

Interfaces

1 interface between chains.

  • A–B · 168 Ų buried · 2 hydrogen bonds · protein-protein

Compared structures

  • 6MD7 · Non-receptor Protein Tyrosine Phosphatase SHP2 in Complex with Allosteric Inhibitor… · the same entry in another collection · chain A against A, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.